AR019388A1 - (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion. - Google Patents

(3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion.

Info

Publication number
AR019388A1
AR019388A1 ARP990103446A ARP990103446A AR019388A1 AR 019388 A1 AR019388 A1 AR 019388A1 AR P990103446 A ARP990103446 A AR P990103446A AR P990103446 A ARP990103446 A AR P990103446A AR 019388 A1 AR019388 A1 AR 019388A1
Authority
AR
Argentina
Prior art keywords
tetrahydro
amino
compositions
processes
preparation
Prior art date
Application number
ARP990103446A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR019388A1 publication Critical patent/AR019388A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe el (3S)tetrahidro-3-furanil(1S), 2R)-3-[[(4-aminofenil)sulfonil]-(isobutil)amino]-1-bencil-2-(fosfooxi) propilcarbamato de calcio, procesospara su uso en el tratamiento de enfermedades causadas por retrovirus, composiciones y procesopara su preparacion. formula (1)
ARP990103446A 1998-07-18 1999-07-14 (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion. AR019388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
AR019388A1 true AR019388A1 (es) 2002-02-13

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103446A AR019388A1 (es) 1998-07-18 1999-07-14 (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion.

Country Status (47)

Country Link
US (3) US6514953B1 (es)
EP (2) EP1240903A3 (es)
JP (1) JP3437553B2 (es)
KR (1) KR100694721B1 (es)
CN (1) CN1188422C (es)
AP (1) AP2001002039A0 (es)
AR (1) AR019388A1 (es)
AT (1) ATE229964T1 (es)
AU (1) AU766056B2 (es)
BG (1) BG105253A (es)
BR (1) BRPI9912156B8 (es)
CA (1) CA2337857C (es)
CO (1) CO5090836A1 (es)
CZ (1) CZ300447B6 (es)
DE (1) DE69904600T2 (es)
DK (1) DK1098898T3 (es)
DZ (1) DZ2845A1 (es)
EA (1) EA003191B1 (es)
EE (1) EE200100038A (es)
ES (1) ES2189450T3 (es)
GB (1) GB9815567D0 (es)
GC (1) GC0000105A (es)
GE (1) GEP20033030B (es)
GT (1) GT199900111A (es)
HR (1) HRP20010046A2 (es)
HU (1) HU229700B1 (es)
ID (1) ID28070A (es)
IL (1) IL140824A (es)
IS (1) IS5808A (es)
JO (1) JO2114B1 (es)
MA (1) MA26660A1 (es)
MY (1) MY122323A (es)
NO (1) NO329676B1 (es)
NZ (1) NZ509291A (es)
OA (1) OA11706A (es)
PA (1) PA8477801A1 (es)
PE (1) PE20000869A1 (es)
PL (1) PL195736B1 (es)
PT (1) PT1098898E (es)
SK (1) SK285311B6 (es)
SV (1) SV1999000096A (es)
TN (1) TNSN99145A1 (es)
TR (1) TR200100111T2 (es)
TW (1) TWI245770B (es)
WO (1) WO2000004033A1 (es)
YU (1) YU3401A (es)
ZA (1) ZA200100417B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
PL204924B1 (pl) * 1999-10-06 2010-02-26 Tibotec Pharm Ltd Heksahydrofuro [2,3-b] furanylo-3-N-{3(1,3-benzodioksolilo-5-sulfonylo) (izobutylo) amino] -1-benzylo-2-hydroksypropylo} karbaminian oraz jego zastosowanie
AU773218B2 (en) * 1999-10-08 2004-05-20 Debiopharm International Sa Fab I inhibitors
EP1560584B1 (en) * 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Fab i inhibitors
NZ535828A (en) 2002-04-26 2007-10-26 Gilead Sciences Inc Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
ES2518316T3 (es) * 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
ATE409485T1 (de) 2003-03-17 2008-10-15 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
EA200501676A1 (ru) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
PL1670448T3 (pl) * 2003-09-30 2008-04-30 Tibotec Pharm Ltd Sulfonamidy inhibitujące HCV
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2543142A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
CN1906196A (zh) 2003-12-22 2007-01-31 吉里德科学公司 具有hiv和hcv抗病毒活性的4＇－取代的卡波韦－和阿巴卡韦－衍生物以及相关化合物
US8450307B2 (en) 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
ES2341120T3 (es) 2004-11-26 2010-06-15 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica.
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
PE20110219A1 (es) 2008-07-08 2011-03-31 Gilead Sciences Inc Sales del compuesto n-[(s)({[(2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfinoil]-l-alaninato de etilo como inhibidores de vih
EA023051B1 (ru) * 2009-04-03 2016-04-29 Осера Терапьютикс, Инк. Кристаллические формы фенилацетата l-орнитина и их применение
EP2432788A1 (en) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
US20120208787A1 (en) * 2009-06-30 2012-08-16 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
EP2477996A1 (en) * 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
US20110165202A1 (en) * 2010-01-07 2011-07-07 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
US20130211108A1 (en) * 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
JP2014513044A (ja) * 2011-02-10 2014-05-29 マイラン ラボラトリーズ リミテッド ホスアンプレナビルカルシウム結晶およびその調製方法
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
WO2013105118A1 (en) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
DK3223829T3 (da) 2014-11-24 2020-02-10 Ucl Business Ltd Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
SMT202000719T1 (it) 2016-02-26 2021-03-15 Debiopharm Int Sa Medicinale per il trattamento d’infezioni del piede diabetico
JP7126520B2 (ja) 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
HUE062061T2 (hu) 2019-02-14 2023-09-28 Debiopharm Int Sa Afabicin készítmény, eljárás annak elõállítására
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
WO1999033792A2 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
ID25551A (id) * 1997-12-24 2000-10-12 Vertex Pharma Bahan baku obat penghambat protease aspartil
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
HK1040625B (zh) * 1998-11-04 2005-04-01 法玛西雅厄普约翰美国公司 用於改善替普拉那维的药物动力学的方法
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
JP2003514910A (ja) * 1999-11-24 2003-04-22 メルク エンド カムパニー インコーポレーテッド Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類

Also Published As

Publication number Publication date
CZ300447B6 (cs) 2009-05-20
ID28070A (id) 2001-05-03
GB9815567D0 (en) 1998-09-16
MY122323A (en) 2006-04-29
KR100694721B1 (ko) 2007-03-15
ZA200100417B (en) 2002-02-27
IS5808A (is) 2001-01-12
ATE229964T1 (de) 2003-01-15
PA8477801A1 (es) 2000-05-24
PE20000869A1 (es) 2000-09-08
NO329676B1 (no) 2010-11-29
CO5090836A1 (es) 2001-10-30
EP1098898B1 (en) 2002-12-18
AP2001002039A0 (en) 2001-03-31
IL140824A (en) 2004-09-27
JP2003521447A (ja) 2003-07-15
EP1098898A1 (en) 2001-05-16
KR20010071952A (ko) 2001-07-31
SK285311B6 (sk) 2006-10-05
EP1240903A3 (en) 2003-02-12
DK1098898T3 (da) 2003-04-07
NO20010282L (no) 2001-03-07
GC0000105A (en) 2005-06-29
MA26660A1 (fr) 2004-12-20
SK762001A3 (en) 2001-10-08
PL345620A1 (en) 2002-01-02
AU766056B2 (en) 2003-10-09
PL195736B1 (pl) 2007-10-31
EA003191B1 (ru) 2003-02-27
HU229700B1 (en) 2014-05-28
HUP0103432A2 (hu) 2002-04-29
IL140824A0 (en) 2002-02-10
DE69904600D1 (de) 2003-01-30
YU3401A (sh) 2005-06-10
DE69904600T2 (de) 2003-11-13
CN1188422C (zh) 2005-02-09
BRPI9912156B1 (pt) 2016-07-26
US6514953B1 (en) 2003-02-04
JP3437553B2 (ja) 2003-08-18
CN1324363A (zh) 2001-11-28
PT1098898E (pt) 2003-04-30
OA11706A (en) 2005-01-13
EP1240903A2 (en) 2002-09-18
US20030100537A1 (en) 2003-05-29
TWI245770B (en) 2005-12-21
GEP20033030B (en) 2003-07-25
BRPI9912156B8 (pt) 2021-05-25
BR9912156A (pt) 2001-04-10
SV1999000096A (es) 2000-07-06
HUP0103432A3 (en) 2003-01-28
GT199900111A (es) 2001-01-05
TNSN99145A1 (fr) 2005-11-10
AU5037999A (en) 2000-02-07
TR200100111T2 (tr) 2002-02-21
CA2337857A1 (en) 2000-01-27
US20030096795A1 (en) 2003-05-22
CA2337857C (en) 2011-01-25
NZ509291A (en) 2003-05-30
EA200100053A1 (ru) 2001-08-27
NO20010282D0 (no) 2001-01-17
EE200100038A (et) 2002-06-17
WO2000004033A1 (en) 2000-01-27
HRP20010046A2 (en) 2002-02-28
BG105253A (en) 2001-12-29
ES2189450T3 (es) 2003-07-01
CZ2001219A3 (cs) 2001-07-11
HK1034261A1 (en) 2001-10-19
JO2114B1 (en) 2000-05-21
DZ2845A1 (fr) 2003-12-01

Similar Documents

Publication Publication Date Title
AR019388A1 (es) (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion.
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
PT96068A (pt) Processo para a producao de proteina biologicamente activa
SE9802729D0 (sv) Novel Compounds
AU2003217055A1 (en) Protein for use in hypoxia related conditions
BR0210941A (pt) Terapia de combinação de oxazolidinonas substituìdas
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
PT100914A (pt) Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
BR0211635A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um indivìduo sofrendo de ou propenso à doença de alzheimer
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DK0841931T3 (da) Farmaceutisk sammensætning
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
WO2001000635A3 (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
PT972521E (pt) Composicao farmaceutica contendo estimuladores de interferao gama
DE60003074D1 (de) Fusidinsäure-derivate
ECSP993057A (es) Tetrahidro -3-furanil (1s,2r)-3-[[(4-aminofenil] sulfonil)] (isobutil) amino] -1- bencil-2 - (fosfonooxi) propilcarbamato de calcio

Legal Events

Date Code Title Description
FC Refusal